Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $455.24M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 2.08M
Average 0.69M
STTK Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Shattuck Labs, Inc.NASDAQ: STTK
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $14.77M (cash outflow) rose 7.8% year over year, ahead of the -29.4% change in trailing-twelve-month net income. Sequentially, it rose 17.3% from the prior quarter. Over 3 fiscal years it compounded at -21.8% a year.
Context
- Net income amounted to 4880.9% of revenue in FY2025, up 3562.8 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$33.52M (-31.3%) for the fiscal year ending Dec 2026, a step up from the -35.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$14.77M+17.3% QoQ
- Last fiscal yearDec 2025
- -$48.81M-35.3% YoY
- LTMMar 2026
- -$49.87M-29.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +7.8% | +29.2% | +21.5 pp |
| 1 year | -35.3% | -31.3% | +3.9 pp |
| 3-year CAGR | -21.8% | -4.2% | +17.6 pp |
| 5-year CAGR | +4.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (48.81M) USD
- Year-over-year change
- +35.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (48.81M) | +35.3% |
| FY2024 | 2024-12-31 | (75.41M) | +13.6% |
| FY2023 | 2023-12-31 | (87.3M) | +14.4% |
| FY2022 | 2022-12-31 | (101.95M) | -126.7% |
| FY2021 | 2021-12-31 | (44.97M) | — |
Net Income vs competitors
How STTK compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -29.4% is the 6th highest of 10, against a peer median of +19.7%.
- Net income amounts to 4987.4% of revenue for STTK, versus a peer median of 58.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $18.8B USD | +53055.5% | +845.2% | — | |
| LTM Sep 2026 | $220.54M USD | -44.5% | -0.4% | 58.2% | |
| LTM Jun 2026 | $195.53M USD | +629.0% | -24.3% | — | |
| LTM Mar 2026 | $162.08M USD | +206.1% | +47.5% | 1363.9% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥150.96M CNY | -47.8% | -67.2% | — |
| LTM Mar 2026 | $49.87M USD | -29.4% | -21.8% | 4987.4% | |
| LTM Mar 2026 | $43.21M USD | -948.8% | — | — | |
| LTM Sep 2026 | $35.76M USD | +37.8% | -13.4% | — | |
| LTM Mar 2026 | $24.38M USD | -35.9% | +2396.3% | 10.7% | |
| LTM Mar 2026 | $18.86M USD | +19.7% | +13.3% | — | |
| Peer median (excluding STTK) | — | +19.7% | +6.5% | 58.2% | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (44.97M) | (101.95M) | (87.3M) | (75.41M) | (48.81M) |
| Depreciation & Amortization | 1.38M | 3.07M | 4.04M | 3.83M | 3.69M |
| Deferred Income Tax | 3.04M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.47M | 6.46M | 6.94M | 9.55M | 7M |
| Change in Working Capital | (23.55M) | (4.46M) | (4.1M) | 3.02M | (785K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.87M | (2.84M) | (5.63M) | 832K | (318K) |
| Other Working Capital | (31.41M) | (1.62M) | 1.53M | 2.19M | (467K) |
| Other Non-Cash Items | 1.52M | 2.38M | (816K) | (1.5M) | (971K) |
| Operating Cash Flow | (57.12M) | (94.5M) | (81.23M) | (60.52M) | (39.88M) |
| Capital Expenditures | (7.93M) | (11.61M) | (407K) | (59K) | (71K) |
| Acquisitions (Net) | 2.52M | 104K | 0 | 0 | 0 |
| Purchases of Investments | (204.09M) | (132.38M) | (79.73M) | (93.55M) | (43.42M) |
| Sales of Investments | 201.58M | 193.33M | 191M | 85.1M | 35.6M |
| Other Investing Activities | (2.52M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (10.44M) | 49.44M | 110.86M | (8.51M) | (7.89M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.93M | 171K | 48.67M | (17K) | 44.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (53K) | 804K | (65K) |
| Financing Cash Flow | 1.93M | 171K | 48.62M | 787K | 44.57M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (65.63M) | (44.89M) | 78.25M | (68.24M) | (3.2M) |
| Free Cash Flow | (65.04M) | (106.11M) | (81.64M) | (60.57M) | (39.95M) |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.